- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01506648
Assessment of Zinc Absorption From a Phytic Acid Rich Complementary Food
November 25, 2016 updated by: Prof. Michael B. Zimmermann, Swiss Federal Institute of Technology
Assessment of Zinc Absorption From a Phytic Acid Rich Complementary Food, Consumed by Young Children Immediately After the Addition of the Enzyme Phytase. A Randomized Single Blind Study
Assessment of zinc absorption from a phytic acid rich complementary food, consumed by young children immediately after the addition of the enzyme phytase.
A randomized single blind study
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ouagadougou, Burkina Faso
- CHU-Yalgado Ouédraogo, Service Pédiatrie
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
1 year to 2 years (Child)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Study not related to a disease.
Nutrition study without drug drug administration.
Assessment of zinc absorption from a phytic acid rich complementary food, consumed by young children immediately after the addition of the enzyme phytase.
A randomized single blind study
Description
Inclusion Criteria:
- 12-24 month old
- Male of female
- Height and weight between -2.0 SD and +2.0 SD with respect to WHO child growth standards.
- No mineral and vitamin supplements 2 weeks prior to the study and during the whole duration of the study
Exclusion Criteria:
- Body temperature ≥ 37.5°C
- Hemoglobin ≤ 7g/dL
- Positive RDT test
- Any metabolic, gastrointestinal or chronic disease (according to the statement of the subject's parent) known chronic diseases at the gastrointestinal tract)
- Long term mediation (that may affect zinc metabolism) during the whole study to interact with zinc metabolism (such as kidney diseases or
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fractional absorption of zinc
Time Frame: 33 days
|
Fractional absorption of zinc is estimated by using the double isotope tracer ratio technique by administering 67Zn as oral and 70Zn as intravenous stable isotopes.The urinary enrichment with both isotopes is measured in a spot urine sample by inductively coupled plasma mass spectrometry.
|
33 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Actual)
April 1, 2012
Study Completion (Actual)
October 1, 2012
Study Registration Dates
First Submitted
January 9, 2012
First Submitted That Met QC Criteria
January 9, 2012
First Posted (Estimate)
January 10, 2012
Study Record Updates
Last Update Posted (Estimate)
November 28, 2016
Last Update Submitted That Met QC Criteria
November 25, 2016
Last Verified
November 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- INSTAPA-FP7-211484
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bioavailability
-
Initiator PharmaNot yet recruiting
-
Fundació EurecatURIACH, S.L.Completed
-
WockhardtCompletedBioavailabilityUnited States
-
Midwest Center for Metabolic and Cardiovascular...NaturmegaCompleted
-
University of AarhusCompletedBioavailabilityDenmark
-
Cessatech A/SSmerud Medical Research International AS; Dantrials ApsCompleted
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
Rousselot BVBABioTeSys GmbHCompleted
-
University of UtahCompleted
-
KGK Science Inc.ChromaDex, Inc.Completed